The Japan Times - Moderna sues Pfizer, BioNTech over Covid vaccine

EUR -
AED 4.339975
AFN 76.814055
ALL 96.492679
AMD 444.535927
ANG 2.115423
AOA 1083.663344
ARS 1692.015434
AUD 1.685082
AWG 2.130101
AZN 2.013663
BAM 1.954639
BBD 2.37329
BDT 144.104396
BGN 1.984592
BHD 0.444336
BIF 3491.925652
BMD 1.181748
BND 1.500509
BOB 8.142163
BRL 6.165657
BSD 1.1783
BTN 106.731597
BWP 15.599733
BYN 3.385189
BYR 23162.260663
BZD 2.369792
CAD 1.617282
CDF 2599.846012
CHF 0.916635
CLF 0.025765
CLP 1017.355497
CNY 8.200091
CNH 8.189295
COP 4371.90291
CRC 584.152989
CUC 1.181748
CUP 31.316322
CVE 110.199537
CZK 24.230684
DJF 209.825355
DKK 7.471252
DOP 74.365824
DZD 153.099053
EGP 55.224195
ERN 17.72622
ETB 183.179684
FJD 2.611077
FKP 0.868664
GBP 0.867943
GEL 3.184858
GGP 0.868664
GHS 12.949308
GIP 0.868664
GMD 86.268024
GNF 10342.855918
GTQ 9.037631
GYD 246.523555
HKD 9.234002
HNL 31.12551
HRK 7.534948
HTG 154.358305
HUF 377.809361
IDR 19918.953296
ILS 3.676034
IMP 0.868664
INR 107.062237
IQD 1543.583048
IRR 49781.134392
ISK 145.012752
JEP 0.868664
JMD 184.420447
JOD 0.837906
JPY 185.77138
KES 151.999706
KGS 103.344316
KHR 4755.17523
KMF 495.152823
KPW 1063.598142
KRW 1729.559546
KWD 0.363045
KYD 0.981917
KZT 582.993678
LAK 25320.958308
LBP 105522.815101
LKR 364.543446
LRD 221.518409
LSL 19.009707
LTL 3.489395
LVL 0.714828
LYD 7.461568
MAD 10.817274
MDL 20.090066
MGA 5230.892634
MKD 61.603405
MMK 2481.807261
MNT 4219.167775
MOP 9.482267
MRU 46.591323
MUR 54.43176
MVR 18.258453
MWK 2043.186263
MXN 20.401229
MYR 4.664955
MZN 75.33688
NAD 19.009707
NGN 1615.426317
NIO 43.36424
NOK 11.451852
NPR 170.770555
NZD 1.97898
OMR 0.453131
PAB 1.1783
PEN 3.964645
PGK 5.052998
PHP 69.145302
PKR 329.485672
PLN 4.218238
PYG 7785.375166
QAR 4.294849
RON 5.093811
RSD 117.310313
RUB 90.746093
RWF 1719.778381
SAR 4.430064
SBD 9.522701
SCR 16.366678
SDG 710.825762
SEK 10.663153
SGD 1.504252
SHP 0.886617
SLE 28.894177
SLL 24780.663673
SOS 672.200685
SRD 44.691391
STD 24459.797516
STN 24.485455
SVC 10.309876
SYP 13069.630436
SZL 19.00571
THB 37.266468
TJS 11.040741
TMT 4.142027
TND 3.41737
TOP 2.845365
TRY 51.538989
TTD 7.97926
TWD 37.331853
TZS 3045.890616
UAH 50.612034
UGX 4192.509477
USD 1.181748
UYU 45.542946
UZS 14469.404578
VES 446.683163
VND 30666.360419
VUV 141.360897
WST 3.227027
XAF 655.567566
XAG 0.015204
XAU 0.000238
XCD 3.193733
XCG 2.123638
XDR 0.815316
XOF 655.567566
XPF 119.331742
YER 281.732962
ZAR 18.960639
ZMK 10637.154271
ZMW 21.945963
ZWL 380.522372
  • RBGPF

    0.1000

    82.5

    +0.12%

  • SCS

    0.0200

    16.14

    +0.12%

  • CMSD

    0.0600

    23.95

    +0.25%

  • BCC

    1.8700

    91.03

    +2.05%

  • NGG

    1.1700

    88.06

    +1.33%

  • BCE

    -0.4900

    25.08

    -1.95%

  • CMSC

    -0.0400

    23.51

    -0.17%

  • RIO

    2.2900

    93.41

    +2.45%

  • RELX

    -0.7100

    29.38

    -2.42%

  • GSK

    1.0600

    60.23

    +1.76%

  • BTI

    0.8400

    62.8

    +1.34%

  • AZN

    5.8700

    193.03

    +3.04%

  • JRI

    0.0900

    12.97

    +0.69%

  • BP

    0.8400

    39.01

    +2.15%

  • RYCEF

    0.2600

    16.88

    +1.54%

  • VOD

    0.4900

    15.11

    +3.24%

Moderna sues Pfizer, BioNTech over Covid vaccine

Moderna sues Pfizer, BioNTech over Covid vaccine

Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world.

Text size:

The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease.

"Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement.

"Pfizer and BioNTech copied this technology, without Moderna's permission, to make Comirnaty," Moderna alleged.

Pfizer and BioNTech said they were aware of the litigation, and each issued statements denying any wrongdoing.

"BioNTech's work is original, and we will vigorously defend against all allegations of patent infringement," the firm said, adding it "respects valid and enforceable intellectual property rights of others."

Pfizer pledged to "vigorously defend against the allegations of the lawsuit."

The mRNA technology used in the Moderna and Pfizer-BioNTech shots differs from that in traditional vaccines, which rely on injecting weakened or dead forms of a virus to allow the immune system to recognize it and build antibodies.

Instead, mRNA vaccines deliver instructions to cells to build a harmless piece of the spike protein found on the surface of the virus that causes Covid-19.

After creating this spike protein, cells can recognize and fight the real virus, hailed as a major advancement in development of vaccines.

- Key tool against deadly pandemic -

The shots have repeatedly been the subject of inaccurate claims that they are dangerous, but health authorities say they are safe and effective.

The lawsuits -- in US district court in Massachusetts, and in regional court in Dusseldorf, Germany -- are not seeking the removal of the rival vaccine or an injunction on future sales.

Moderna said it had begun building up the technology in 2010 and patented work on corona viruses in 2015 and 2016, which allowed for rollout of its shots in "record time" after the pandemic struck.

The virus has killed at least 6.48 million people worldwide since 2020 and made nearly 600 million ill, according to a Johns Hopkins University tracker.

In addition to death and suffering, the disease has led to a re-shaping of life ranging from a change in norms on working from home to a scrambling of supply chains and workforces.

Moderna said it pledged in October 2020 not to enforce its Covid-19-related patents while the pandemic continued, but less than two years later changed that stance as the fight shifted gears.

"Moderna expected companies such as Pfizer and BioNTech to respect its intellectual property rights and would consider a commercially reasonable license should they request one for other markets," it said.

"Pfizer and BioNTech have failed to do so," the firm added.

These types of lawsuits are not unheard of in the pharmaceutical industry, where patents can be worth billions of dollars, and can take years to resolve.

"It is an unfortunate but rather regular occurrence that other companies make allegations that a successful product potentially infringes their intellectual property rights," BioNTech said in a statement.

M.Sugiyama--JT